Latest Kaiser Health News Stories
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
Even under a decent plan, you’ll have to dig deep in your pocket for crowns, bridges and implants. The mouth isn’t covered by insurance the same way as the rest of the body, and this division has deep roots in history and tradition.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call discuss President Donald Trump’s proposals to control prescription drug prices and the efforts to sell the plan to lawmakers and the public. Also, Rovner interviews emeritus law professor Timothy Jost about the state of the Affordable Care Act.
As many as 16 million people in the United States have undiagnosed or uncorrected vision problems that could be fixed with eyeglasses, contact lenses or surgery.
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
All private health plans, Medicare, state Medicaid programs and the VA now cover some e-visits — albeit with restrictions.
Federal law prohibits them from using the coupons drugmakers offer to help patients cover their share of a medicine’s cost.
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post examine how even after Republicans failed to repeal and replace the Affordable Care Act, the health care debate continues to roil politics. They discuss how Republicans in Congress have shifted their ACA messaging and how the Democrats are looking to Medicare expansion. They also discuss state efforts to expand Medicaid and drug pricing. And they spend a moment talking about Congress’ push to do something about the opioid crisis.
On April 1, Medicare launched a major initiative — a diabetes prevention program for seniors and people with serious disabilities— that is available in only a few cities.
As free-standing emergency departments multiply, the Medicare Payment Advisory Commission recommends a 30 percent reduction in some federal reimbursements for those within 6 miles of a hospital.
Under new federal rules unveiled this week, these privately run alternatives to traditional Medicare might provide air conditioners, rides to medical appointments and home-delivered meals.
Treatment has been terminated for some seniors because therapists told them they weren’t making enough progress or that they had reached their annual limit. We examine the treatment benefits and the barriers under Medicare’s coverage rules for therapy.
The state’s ambitious payment overhaul has begun to demonstrate savings and a change in culture, say new reports.
Starting in April, new Medicare cards will be issued to the program’s 59 million enrollees. The new cards address serious security concerns, yet there are growing “scams” linked to the rollout.
Last month’s budget deal means Medicare beneficiaries are eligible for physical and occupational therapy indefinitely. Plus, prescription drug costs will fall for more seniors.